These tumor antigen specific cytotoxic CD8+ T cells primed by antigen-presenting dendritic cells represent the key cell subset in most immunotherapy trials in HCC that have demonstrated positive influence on patient survival [7, 8]. Here, CD8A is linked to neoplasm.